🧬 ERA (Endometrial Receptivity Analysis): Timing the Transfer Window

The Endometrial Receptivity Analysis (ERA) test, developed by Igenomix (now part of Vitrolife), promises to personalize the timing of embryo transfer by identifying each patient's individual window of implantation (WOI) — the brief period when the endometrium is biologically ready to accept an embryo. The test is marketed particularly to patients with recurrent implantation failure (RIF) as a potential explanation for unexplained transfer failures.

The science is fascinating. The marketing is enthusiastic. But the 2022-2024 randomized controlled trial evidence has been a bucket of cold water on the routine use of this test. Here is what you need to know.

What the ERA Test Measures

The ERA analyzes the expression of 238 genes in a small biopsy of endometrial tissue, taken in a mock cycle that exactly replicates a planned embryo transfer cycle. The test classifies the endometrium as:

• Receptive: the WOI is appropriately timed and transfer should proceed as planned
• Pre-receptive: the WOI is later than the standard timing; transfer should be delayed (typically by 12 to 24 hours)
• Post-receptive: the WOI has already passed; transfer should be moved earlier

The Theoretical Appeal

In natural pregnancy, implantation happens within a window of roughly 24 to 48 hours, typically around cycle days 19 to 23 in a 28-day cycle. Standard medicated FET protocols time the transfer based on a fixed number of days of progesterone exposure (typically 5 days for a blastocyst). If a particular patient's WOI is slightly displaced — earlier or later than average — a standard transfer protocol could miss the window.

For a patient who has had multiple unexplained failed transfers of good-quality embryos, the idea of a personalized timing test is genuinely appealing.

How the Test Is Performed

A mock FET cycle is run with hormonal preparation identical to what will be used in the actual transfer cycle. On the day that the embryo would have been transferred (usually progesterone day 5 for blastocysts), an endometrial biopsy is taken. The tissue is shipped to Igenomix for analysis. Results typically come back in 2 to 3 weeks.

If the result is non-receptive, the actual transfer cycle is adjusted accordingly. A subset of patients are recommended to repeat the test if the result is borderline.

Cost

• Test cost: typically $1,000 to $1,500 USD plus the cost of the mock cycle (medications, monitoring)
• Total typical out-of-pocket: $2,000 to $3,500
• Cycle time delay: at least one extra month

The Early Observational Studies: Encouraging

Early retrospective and small prospective studies suggested benefit in women with RIF. Igenomix-sponsored data reported clinical pregnancy improvements with personalized transfer timing.

The Pivotal RCT: Simon 2020 / 2022

A large multicenter RCT by Simon et al., initially published in 2020 and updated in 2022, randomized 458 women undergoing their first FET to either personalized transfer (using ERA) or standard transfer timing.

Results:

• Cumulative live birth rate: similar between groups
• The personalization arm did not outperform standard timing in the first transfer attempt
• Subgroup analyses were not definitively positive

The Doyle 2022 Study

Doyle et al., published in JAMA in 2022, evaluated ERA in a large clinical cohort and found no improvement in clinical pregnancy or live birth rates when ERA was used vs standard timing.

The 2024 Cochrane Update

The Cochrane systematic review on personalized embryo transfer timing concluded that current evidence does not support routine use of ERA in unselected patients undergoing IVF.

Where the Evidence May Still Support ERA

A narrower potential niche:

• Patients with multiple failed transfers of chromosomally normal (PGT-A euploid) embryos in whom other explanations have been ruled out
• Carefully selected RIF cases where the clinician believes timing displacement is plausible

Even in these subgroups, RCT evidence remains limited. Some experts argue ERA may help, others argue the test result is itself noisy and may lead to false adjustments.

Practical Concerns

• Cycle-to-cycle variability: a patient's WOI may shift between cycles, and a result from one mock cycle may not predict the next
• Hormonal preparation differences: the test only validates the specific protocol used in the mock cycle; switching protocols may invalidate the result
• The biopsy itself: requires an additional invasive procedure with mild discomfort and very small infection risk

How to Think About It

For a patient considering their first FET, the evidence does not support adding ERA. For a patient who has experienced multiple unexplained failed transfers of high-quality embryos, the conversation is more nuanced — and worth having with your RE. But the test is not a magic bullet, and the cost-benefit math has shifted unfavorably compared to a few years ago.

What to Ask Your Clinic

• Do you routinely offer ERA, and in what circumstances?
• What outcomes have you seen at this clinic when ERA is used?
• What does this cost out of pocket, and what cycle delay should I expect?
• Are there other tests or workups (immune, hematologic, uterine cavity) that should come first?
• How does this fit with current ASRM and Cochrane guidance?

Confirm with your reproductive endocrinologist before adding ERA to your treatment plan. To compare clinics that routinely offer evidence-based testing, see the Fertility Link Navigator.